Sputum tests in the diagnosis and monitoring of asthma

Annals of Allergy, Asthma and Immunology

Volumn 93, Issue 2, 2004, Pages

  Kim, Chang Keun ^a,b   Hagan, John B ^b  

^a Inje University College of Medicine   (South Korea)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID;

ASTHMA; BRONCHITIS; BRONCHUS BIOPSY; CELL COUNT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DIAGNOSTIC VALUE; HUMAN; IMMUNOCHEMISTRY; INTERMETHOD COMPARISON; LUNG LAVAGE; MEDICAL LITERATURE; MEDLINE; NON INVASIVE MEASUREMENT; OCCUPATIONAL ASTHMA; PATIENT MONITORING; PRIORITY JOURNAL; PUBLICATION; REVIEW; SPUTUM ANALYSIS; TRACHEOBRONCHIAL TOILET;

EID: 4344671808     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1081-1206(10)61462-7     Document Type: Review

References (81)

1. Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet. 2002;360:1715-1721.
2. Kharitonov SA, Barnes PJ. Exhaled markers of pulmonary disease. Am J Respir Crit Care Med. 2001;163:1693-1722.
3. Smith A. Diagnosing asthma comparisons between exhaled nitric oxide measurements and conventional tests. Am J Respir Crit Care Med. 2004;169:473-478.
4. Mannino DM, Homa DM, Akinbami LJ, Moorman JE, Gwynn C, Redd SC. Surveillance for asthma-United States, 1980-1999. MMWR Surveill Summ. 2002;51:1-13.
5. Weiss KB, Sullivan SD. The health economics of asthma and rhinitis I: assessing the economic impact. J Allergy Clin Immunol. 2001;107:3-8.
6. Liard R, Leynaert B, Zureik M, Beguin FX, Neukirch F. Using Global Initiative for Asthma guidelines to assess asthma severity in populations. Eur Respir J. 2000;16:615-620.
7. Busse WW, Rosenwasser LJ. Mechanisms of asthma. J Allergy Clin Immunol. 2003;111(Suppl):S799-S804.
8. ten Brinke A, Zwinderman AH, Sterk PJ, Rabe KF, Bel EH. Factors associated with persistent airflow limitation in severe asthma. Am J Respir Crit Care Med. 2001;164:744-748.
9. Louis R, Lau LC, Bron AO, Roldaan AC, Radermecker M, Djukanovic R. The relationship between airways inflammation and asthma severity. Am J Respir Crit Care Med. 2000;161:9-16.
10. Wenzel SE, Szefler SJ, Leung DY, Sloan SI, Rex MD, Martin RJ. Bronchoscopic evaluation of severe asthma persistent inflammation associated with high dose glucocorticoids. Am J Respir Crit Care Med. 1997;156:737-743.
11. Romagnoli M, Vachier I, Tarodo de la Fuente P, et al. Eosinophilic inflammation in sputum of poorly controlled asthmatics. Eur Respir J. 2002;20:1370-1377.
12. Szefler SJ, Martin RJ, King TS, et al, Asthma Clinical Research Network of the National Heart, Lung, and Blood Institute. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol. 2002;109:410-418.
13. in't Veen JC, Smits HH, Hiemstra PS, Zwinderman AE, Sterk PJ, Bel EH. Lung function and sputum characteristics of patients with severe asthma during an induced exacerbation by double-blind steroid withdrawal. Am J Respir Crit Care Med. 1999;160:93-99.
14. Pizzichini MM, Pizzichini E, Clelland L, et al. Sputum in severe exacerbations of asthma: kinetics of inflammatory indices after prednisone treatment. Am J Respir Crit Care Med. 1997;155:1501-1508.
15. Sont JK, Willems LN, Bel EH, van Krieken JH, Vandenbroucke JP, Sterk PJ. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment: The AMPUL Study Group. Am J Respir Crit Care Med. 1999;159:1043-1051.
16. 20 methacholine. Am J Respir Crit Care Med. 2001;163:1546-1550.
17. van den Berge M, Kerstjens HA, de Reus DM, Kauffman HF, Koeter GH, Postma DS. Provocation with adenosine 5′-monophosphate increases sputum eosinophils. Chest. 2003;123(Suppl):417S.
18. Fahy JV, Wong H, Liu J, Boushey HA. Comparison of samples collected by sputum induction and bronchoscopy from asthmatic and healthy subjects. Am J Respir Crit Care Med. 1995;152:53-58.
19. Gibson PG, Fujimura M, Niimi A. Eosinophilic bronchitis: clinical manifestations and implications for treatment. Thorax. 2002;57:178-182.
20. Jatakanon A, Kharitonov S, Lim S, Barnes PJ. Effect of differing doses of inhaled budesonide on markers of airway inflammation in patients with mild asthma. Thorax. 1999;54:108-114.
21. Parameswaran K, Inman MD, Watson RM, et al. Protective effects of fluticasone on allergen-induced airway responses and sputum inflammatory markers. Can Respir J. 2000;7:313-319.
22. McIvor RA, Pizzichini E, Turner MO, Hussack P, Hargreave FE, Sears MR. Potential masking effects of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Med. 1998;158:924-930.
23. Pizzichini MM, Pizzichini E, Efthimiadis A, et al. Asthma and natural colds. Inflammatory indices in induced sputum: a feasibility study. Am J Respir Crit Care Med. 1998;158:1178-1184.
24. Fahy JV, Liu J, Wong H, Boushey HA. Cellular and biochemical analysis of induced sputum from asthmatic and from healthy subjects. Am Rev Respir Dis. 1993;147:1126-1131.
25. Pizzichini E, Pizzichini MM, Efthimiadis A, et al. Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements. Am J Respir Crit Care Med. 1996;1154:308-317.
26. Belda J, Leigh R, Parameswaran K, O'Byrne PM, Sears MR, Hargreave FE. Induced sputum cell counts in healthy adults. Am J Respir Crit Care Med. 2000;161:475-478.
27. Djukanovic R, Sterk PJ, Fahy JV, Hargreave FE. Standardised methodology of sputum induction and processing. Eur Respir J Suppl. 2002;37:24S-39S.
28. Smith CM, Anderson SD. Inhalation provocation tests using nonisotonic aerosols. J Allergy Clin Immunol. 1989;84:781-790.
29. Tamaoki J, Kondo M, Kuroda H, et al. Validity and safety of sputum induction by inhaled uridine 5′-triphosphate. Am J Respir Crit Care Med. 2001;164:378-381.
30. Fahy JV, Boushey HA, Lazarus SC, et al, NHLBI Asthma Clinical Research Network. Safety and reproducibility of sputum induction in asthmatic subjects in a multicenter study. Am J Respir Crit Care Med. 2001;163:1470-1475.
31. ten Brinke A, de Lange C, Zwinderman AH, Rabe KF, Sterk PJ, Bel EH. Sputum induction in severe asthma by a standardized protocol: predictors of excessive bronchoconstriction. Am J Respir Crit Care Med. 2001;164:749-753.
32. Sutherland ER, Pak J, Langmack EL, Silkoff PE, Martin RJ. Safety of sputum induction in moderate-to-severe chronic obstructive pulmonary disease. Respir Med. 2002;96:482-486.
33. Kips JC, Fahy JV, Hargreave FE, Ind PW, in't Veen JC. Methods for sputum induction and analysis of induced sputum: a method for assessing airway inflammation in asthma. Eur Respir J Suppl. 1998;26:9S-12S.
34. Boulet LP, Turcotte H, Tennina S. Comparative efficacy of salbutamol, ipratropium, and cromoglycate in the prevention of bronchospasm induced by exercise and hyperosmolar challenges. J Allergy Clin Immunol. 1989;83:882-887.
35. Wong HH, Fahy JV. Safety of one method of sputum induction in asthmatic subjects. Am J Respir Crit Care Med. 1997;156:299-303.
36. Maestrelli P, Saetta M, Di Stefano A, et al. Comparison of leukocyte counts in sputum, bronchial biopsies, and bronchoalveolar lavage. Am J Respir Crit Care Med. 1995;152:1926-1931.
37. Keatings VM, Evans DJ, O'Connor BJ, Barnes PJ. Cellular profiles in asthmatic airways: a comparison of induced sputum, bronchial washings, and bronchoalveolar lavage fluid. Thorax. 1997;52:372-374.
38. Grootendorst DC, Sont JK, Willems LN, et al. Comparison of inflammatory cell counts in asthma: induced sputum vs bronchoalveolar lavage and bronchial biopsies. Clin Exp Allergy. 1997;27:769-779.
39. Pizzichini E, Pizzichini MM, Kidney JC, et al. Induced sputum, bronchoalveolar lavage and blood from mild asthmatics: inflammatory cells, lymphocyte subsets and soluble markers compared. Eur Respir J. 1998;11:828-834.
40. Chodosh S, Zaccheo C, Segal M. The cytology and histochemistry of sputum cells. Am Rev Respir Dis. 1961;85:635-648.
41. Linder J, Rennard S. Cytology of normal bronchoalveolar lavage. In: Bronchoalveolar Lavage. Chicago, IL: ASCP Press; 1988:45-65.
42. Spanevello A, Confalonieri M, Sulotto F, et al. Induced sputum cellularity. Reference values and distribution in normal volunteers. Am J Respir Crit Care Med. 2000;162:1172-1174.
43. Fahy JV, Steiger DJ, Liu J, Basbaum CB, Finkbeiner WE, Boushey HA. Markers of mucus secretion and DNA levels in induced sputum from asthmatic and from healthy subjects. Am Rev Respir Dis. 1993;147:1132-1137.
44. Gelder CM, Thomas PS, Yates DH, Adcock IM, Morrison JF, Barnes PJ. Cytokine expression in normal, atopic, and asthmatic subjects using the combination of sputum induction and the polymerase chain reaction. Thorax. 1995;50:1033-1037.
45. Spanevello A, Beghe B, Bianchi A, et al. Comparison of two methods of processing induced sputum: selected versus entire sputum. Am J Respir Crit Care Med. 1998;157:665-668.
46. Belda J, Parameswaran K, Hargreave FE. Comparison of two methods of processing induced sputum: selected versus entire sputum. Am J Respir Crit Care Med. 1998;158:680-682.
47. Pizzichini E, Pizzichini MM, Efthimiadis A, Hargreave FE, Dolovich J. Measurement of inflammatory indices in induced sputum: effects of selection of sputum to minimize salivary contamination. Eur Respir J. 1996;9:1174-1180.
48. in 't Veen JC, de Gouw HW, Smits HH, et al. Repeatability of cellular and soluble markers of inflammation in induced sputum from patients with asthma. Eur Respir J. 1996;9:2441-2447.
49. Kim JS, Hackley GH, Okamoto K, Rubin BK. Sputum processing for evaluation of inflammatory mediators. Pediatr Pulmonol. 2001;32:152-158.
50. Grebski E, Peterson C, Medici TC. Effect of physical and chemical methods of homogenization on inflammatory mediators in sputum of asthma patients. Chest. 2001;119:1521-1525.
51. Simpson JL, Gibson PG, Wark PA. Optimization of sputum-processing methods for the measurement of interleukin-5: effects of protease inhibition. Respirology. 2002;7:111-116.
52. Bacci E, Cianchetti S, Paggiaro PL, et al. Comparison between hypertonic and isotonic saline-induced sputum in the evaluation of airway inflammation in subjects with moderate asthma. Clin Exp Allergy. 1996;26:1395-1400.
53. Efthimiadis A, Jayaram L, Weston S, Carruthers S, Hargreave FE. Induced sputum: time from expectoration to processing. Eur Respir J. 2002;19:706-708.
54. Popov TA, Pizzichini MM, Pizzichini E, et al. Some technical factors influencing the induction of sputum for cell analysis. Eur Respir J. 1995;8:559-565.
55. Hunter CJ, Brightling CE, Woltmann G, Wardlaw AJ, Pavord ID. A comparison of the validity of different diagnostic tests in adults with asthma. Chest. 2002;121:1051-1057.
56. Lemiere C, Walker C, O'Shaughnessy D, Efthimiadis A, Hargreave FE, Sears MR. Differential cell counts in sputum in respiratory epidemiology: a pilot study. Chest. 2001;120:1107-1113.
57. van Den Toorn LM, Prins JB, Overbeek SE, Hoogsteden HC, de Jongste JC. Adolescents in clinical remission of atopic asthma have elevated exhaled nitric oxide levels and bronchial hyperresponsiveness. Am J Respir Crit Care Med. 2000;162:953-957.
58. van den Toorn LM, Overbeek SE, de Jongste JC, Leman K, Hoogsteden HC, Prins JB. Airway inflammation is present during clinical remission of atopic asthma. Am J Respir Crit Care Med. 2001;164:2107-2113.
59. Warke TJ, Fitch PS, Brown V, et al. Outgrown asthma does not mean no airways inflammation. Eur Respir J. 2002;19:284-287.
60. Turner MO, Hussack P, Sears MR, Dolovich J, Hargreave FE. Exacerbations of asthma without sputum eosinophilia. Thorax. 1995;50:1057-1061.
61. Wenzel SE, Schwartz LB, Langmack EL, et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med. 1999;160:1001-1008.
62. Fahy JV, Kim KW, Liu J, Boushey HA. Prominent neutrophilic inflammation in sputum from subjects with asthma exacerbation. J Allergy Clin Immunol. 1995;95:843-852.
63. Douwes J, Gibson P, Pekkanen J, Pearce N. Non-eosinophilic asthma: importance and possible mechanisms. Thorax. 2002;57:643-648.
64. Green RH, Brightling CE, Woltmann G, Parker D, Wardlaw AJ, Pavord ID. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax. 2002;57:875-879.
65. Gibson PG, Dolovich J, Denburg J, Ramsdale EH, Hargreave FE. Chronic cough: eosinophilic bronchitis without asthma. Lancet. 1989;1:1346-1348.
66. Niimi A, Amitani R, Suzuki K, Tanaka E, Murayama T, Kuze F. Eosinophilic inflammation in cough variant asthma. Eur Respir J. 1998;11:1064-1069.
67. Kim C, Hagan J, Kita H. Eosinophilic airway inflammation as an underlying mechanism in certain patients with chronic cough but without asthma. Am J Respir Crit Care Med. 2003;167:A633.
68. Brightling CE, Ward R, Wardlaw AJ, Pavord ID. Airway inflammation, airway responsiveness and cough before and after inhaled budesonide in patients with eosinophilic bronchitis. Eur Respir J. 2000;15:682-686.
69. Rytila P, Metso T, Petays T, et al. Eosinophilic airway inflammation as an underlying mechanism of undiagnosed prolonged cough in primary healthcare patients. Respir Med. 2002;96:52-58.
70. Rijcken B, Schouten JP, Weiss ST, Speizer FE, van der Lende R. The relationship between airway responsiveness to histamine and pulmonary function level in a random population sample. Am Rev Respir Dis. 1988;137:826-832.
71. Epstein PE. Inhaled corticosteroids and chronic obstructive pulmonary disease: are we barking up the wrong tracheobronchial tree? Ann Intern Med. 2003;138:1001-1002.
72. Barnes PJ. Inhaled corticosteroids are not beneficial in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161:342-344; discussion 344.
73. Calverley PM. Inhaled corticosteroids are beneficial in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161:341-342; discussion 344.
74. 1 in patients with chronic obstructive pulmonary disease: a meta-analysis [comment]. Ann Intern Med. 2003;138:969-973.
75. Barnes PJ. New concepts in chronic obstructive pulmonary disease. Annu Rev Med. 2003;54:113-129.
76. Pizzichini E, Pizzichini MM, Gibson P, et al. Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis. Am J Respir Crit Care Med. 1998;158:1511-1517.
77. Lemiere C, Pizzichini MM, Balkissoon R, et al. Diagnosing occupational asthma: use of induced sputum. Eur Respir J. 1999;13:482-488.
78. Tarlo SM. Recent advances in occupational asthma. Curr Opin Pulm Med. 2000;6:145-150.
79. Lemiere C, Efthimiadis A, Hargreave FE. Occupational eosinophilic bronchitis without asthma: an unknown occupational airway disease. J Allergy Clin Immunol. 1997;100:852-853.
80. Maestrelli P, Calcagni PG, Saetta M, et al. Sputum eosinophilia after asthmatic responses induced by isocyanates in sensitized subjects. Clin Exp Allergy. 1994;24:29-34.
81. Anees W, Huggins V, Pavord ID, Robertson AS, Burge PS. Occupational asthma due to low molecular weight agents: eosinophilic and non-eosinophilic variants. Thorax. 2002;57:231-236.